BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 38691867)

  • 41. Surgical Management of Skull Base and Spine Chordomas.
    Passer JZ; Alvarez-Breckenridge C; Rhines L; DeMonte F; Tatsui C; Raza SM
    Curr Treat Options Oncol; 2021 Mar; 22(5):40. PubMed ID: 33743089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The biological basis for modern treatment of chordoma.
    Diaz RJ; Cusimano MD
    J Neurooncol; 2011 Sep; 104(2):411-22. PubMed ID: 21384217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The cutting-edge progress of immune-checkpoint blockade in lung cancer.
    Zhou F; Qiao M; Zhou C
    Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current opinion in otolaryngology and head and neck surgery: clival chordoma and its management.
    Snyderman CH; Gardner PA
    Curr Opin Otolaryngol Head Neck Surg; 2020 Apr; 28(2):118-121. PubMed ID: 32102007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.
    Xu J; Shi Q; Wang B; Ji T; Guo W; Ren T; Tang X
    Front Immunol; 2023; 14():1257254. PubMed ID: 37720221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chordoma.
    Casali PG; Stacchiotti S; Sangalli C; Olmi P; Gronchi A
    Curr Opin Oncol; 2007 Jul; 19(4):367-70. PubMed ID: 17545801
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proton radiation therapy for chordomas and chondrosarcomas of the skull base.
    Hug EB; Slater JD
    Neurosurg Clin N Am; 2000 Oct; 11(4):627-38. PubMed ID: 11082173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chordoma dedifferentiation after proton beam therapy: a case report and review of the literature.
    Frankl J; Grotepas C; Stea B; Lemole GM; Chiu A; Khan R
    J Med Case Rep; 2016 Oct; 10(1):280. PubMed ID: 27729085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma.
    Kitamura Y; Sasaki H; Yoshida K
    Brain Tumor Pathol; 2017 Apr; 34(2):78-90. PubMed ID: 28432450
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endoscopic Endonasal Management of Skull Base Chordomas: Surgical Technique, Nuances, and Pitfalls.
    Mangussi-Gomes J; Beer-Furlan A; Balsalobre L; Vellutini EA; Stamm AC
    Otolaryngol Clin North Am; 2016 Feb; 49(1):167-82. PubMed ID: 26614836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel therapeutic targets in chordoma.
    Bydon M; Papadimitriou K; Witham T; Wolinsky JP; Bydon A; Sciubba D; Gokaslan Z
    Expert Opin Ther Targets; 2012 Nov; 16(11):1139-43. PubMed ID: 22860993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Skull base chordoma.
    Mendenhall WM; Mendenhall CM; Lewis SB; Villaret DB; Mendenhall NP
    Head Neck; 2005 Feb; 27(2):159-65. PubMed ID: 15641104
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.
    Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP
    Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.